Switch theme
Sign up to access all valuation multiples
Guangzhou Wondfo Biotech Co Ltd manufactures medical diagnostic tests. Its products include immunodiagnostic rapid test kits, including fertility, which include pregnancy HCG, ovulation LH, and others. The company's products are used in a clinical test, field test, and personal health management, among others.
1992
n/a
LTM Revenue $447M
LTM EBITDA $153M
$1.2B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Guangzhou Wondfo Biotech has a last 12-month revenue (LTM) of $447M and a last 12-month EBITDA of $153M.
In the most recent fiscal year, Guangzhou Wondfo Biotech achieved revenue of $425M and an EBITDA of $129M.
Guangzhou Wondfo Biotech expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Guangzhou Wondfo Biotech valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $447M | XXX | $425M | XXX | XXX | XXX |
| Gross Profit | $286M | XXX | $273M | XXX | XXX | XXX |
| Gross Margin | 64% | XXX | 64% | XXX | XXX | XXX |
| EBITDA | $153M | XXX | $129M | XXX | XXX | XXX |
| EBITDA Margin | 34% | XXX | 30% | XXX | XXX | XXX |
| EBIT | $93.1M | XXX | $91.3M | XXX | XXX | XXX |
| EBIT Margin | 21% | XXX | 21% | XXX | XXX | XXX |
| Net Profit | $82.6M | XXX | $78.0M | XXX | XXX | XXX |
| Net Margin | 18% | XXX | 18% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Guangzhou Wondfo Biotech's stock price is CNY 21 (or $3).
Guangzhou Wondfo Biotech has current market cap of CNY 10.2B (or $1.4B), and EV of CNY 8.9B (or $1.2B).
See Guangzhou Wondfo Biotech trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.2B | $1.4B | XXX | XXX | XXX | XXX | $0.17 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Guangzhou Wondfo Biotech has market cap of $1.4B and EV of $1.2B.
Guangzhou Wondfo Biotech's trades at 2.9x EV/Revenue multiple, and 9.5x EV/EBITDA.
Equity research analysts estimate Guangzhou Wondfo Biotech's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Guangzhou Wondfo Biotech has a P/E ratio of 17.2x.
See valuation multiples for Guangzhou Wondfo Biotech and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1.4B | XXX | $1.4B | XXX | XXX | XXX |
| EV (current) | $1.2B | XXX | $1.2B | XXX | XXX | XXX |
| EV/Revenue | 2.8x | XXX | 2.9x | XXX | XXX | XXX |
| EV/EBITDA | 8.1x | XXX | 9.5x | XXX | XXX | XXX |
| EV/EBIT | 13.3x | XXX | 13.5x | XXX | XXX | XXX |
| EV/Gross Profit | 4.3x | XXX | n/a | XXX | XXX | XXX |
| P/E | 17.2x | XXX | 18.2x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 204.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialGuangzhou Wondfo Biotech's last 12 month revenue growth is 13%
Guangzhou Wondfo Biotech's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.
Guangzhou Wondfo Biotech's rule of 40 is 44% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Guangzhou Wondfo Biotech's rule of X is 66% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Guangzhou Wondfo Biotech and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 13% | XXX | 13% | XXX | XXX | XXX |
| EBITDA Margin | 34% | XXX | 30% | XXX | XXX | XXX |
| EBITDA Growth | 1% | XXX | 11% | XXX | XXX | XXX |
| Rule of 40 | 44% | XXX | 43% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 66% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 8% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 13% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 43% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Australian Clinical Labs | XXX | XXX | XXX | XXX | XXX | XXX |
| Clarity Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| CurveBeam AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Cyclopharm | XXX | XXX | XXX | XXX | XXX | XXX |
| Healius | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Guangzhou Wondfo Biotech acquired XXX companies to date.
Last acquisition by Guangzhou Wondfo Biotech was XXXXXXXX, XXXXX XXXXX XXXXXX . Guangzhou Wondfo Biotech acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Guangzhou Wondfo Biotech founded? | Guangzhou Wondfo Biotech was founded in 1992. |
| Where is Guangzhou Wondfo Biotech headquartered? | Guangzhou Wondfo Biotech is headquartered in China. |
| Is Guangzhou Wondfo Biotech publicy listed? | Yes, Guangzhou Wondfo Biotech is a public company listed on SHE. |
| What is the stock symbol of Guangzhou Wondfo Biotech? | Guangzhou Wondfo Biotech trades under 300482 ticker. |
| When did Guangzhou Wondfo Biotech go public? | Guangzhou Wondfo Biotech went public in 2015. |
| Who are competitors of Guangzhou Wondfo Biotech? | Similar companies to Guangzhou Wondfo Biotech include e.g. Australian Clinical Labs, Clarity Pharmaceuticals, CurveBeam AI, Cyclopharm. |
| What is the current market cap of Guangzhou Wondfo Biotech? | Guangzhou Wondfo Biotech's current market cap is $1.4B |
| What is the current revenue of Guangzhou Wondfo Biotech? | Guangzhou Wondfo Biotech's last 12 months revenue is $447M. |
| What is the current revenue growth of Guangzhou Wondfo Biotech? | Guangzhou Wondfo Biotech revenue growth (NTM/LTM) is 13%. |
| What is the current EV/Revenue multiple of Guangzhou Wondfo Biotech? | Current revenue multiple of Guangzhou Wondfo Biotech is 2.8x. |
| Is Guangzhou Wondfo Biotech profitable? | Yes, Guangzhou Wondfo Biotech is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Guangzhou Wondfo Biotech? | Guangzhou Wondfo Biotech's last 12 months EBITDA is $153M. |
| What is Guangzhou Wondfo Biotech's EBITDA margin? | Guangzhou Wondfo Biotech's last 12 months EBITDA margin is 34%. |
| What is the current EV/EBITDA multiple of Guangzhou Wondfo Biotech? | Current EBITDA multiple of Guangzhou Wondfo Biotech is 8.1x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
